SPY326.52+2.56 0.79%
DIA264.35+1.07 0.41%
IXIC10,745.28+157.46 1.49%
News
AUPH
--
0.00%
--
Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that it will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the markets close. Aurinia’s executive team will host a conference call to
Business Wire · 4d ago
Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 5d ago
Aurinia secures $200M capital raise
Aurinia Pharmaceuticals (AUPH -2.3%) has closed its public offering of ~13.3M common shares at $15 per share. Gross proceeds were ~$200M.
seekingalpha · 6d ago
Aurinia Closes US$200 Million Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the closing of its previously announced underwritten pu
Business Wire · 6d ago
Why Aurinia Pharmaceuticals Dived by 16% on Thursday
MotleyFool.com · 07/23 22:59
Mid-Afternoon Market Update: Dow Tumbles 400 Points; Milestone Pharmaceuticals Shares Gain
Toward the end of trading Thursday, the Dow traded down 1.49% to 26604.41 while the NASDAQ fell 2.37% to 10,452.62. The S&P also fell, dropping 1.33% to 3,232.34.
Benzinga · 07/23 19:15
Mid-Day Market Update: Brightcove Surges On Upbeat Q2 Results; Aurinia Pharmaceuticals Shares Slide
Midway through trading Thursday, the Dow traded down 0.46% to 26,882.42 while the NASDAQ fell 0.64% to 10,637.29. The S&P also fell, dropping 0.29% to 3,266.66.
Benzinga · 07/23 16:10
Aurinia Pharmaceuticals shares are trading lower after the company announced On Wednesday a $200 million public offering of common shares.
Benzinga · 07/23 11:46
Aurinia Prices US$200 Million Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced the pricing of its underwritten public offering of 13,333,334 common shares (the "Offering"). The shares are being sold at a public offering price of US$15.00 per share.
Benzinga · 07/23 09:41
Aurinia Prices US$200 Million Public Offering of Common Shares
Aurinia Prices US$200 Million Public Offering of Common Shares
Business Wire · 07/23 03:05
Aurinia Pharmaceuticals shares are trading lower after the company announced a public offering of common shares. No size was disclosed.
Benzinga · 07/22 20:11
Aurinia Announces Public Offering Of Common Shares; Size Not Disclosed
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on
Benzinga · 07/22 20:08
Aurinia Announces Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that it has commenced a registered underwritten public
Business Wire · 07/22 20:08
Aurinia Pharmaceuticals shares are trading higher after the company's new drug application for Voclosporin was accepted by the FDA for priority review.
Benzinga · 07/22 16:18
Why Aurinia Pharmaceuticals Is Up Today
What happened? Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) are up by 10.4% as of 11:15 a.m. EDT on Wednesday, after the company announced that the U.S. Food and Drug Administration (FDA) accepted the filing of a New Drug Application (NDA) for Voclosporin.
Motley Fool · 07/22 15:31
NAK, EXK among premarket gainers
Seeking Alpha - Article · 07/22 12:16
The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21)
Benzinga · 07/22 11:24
Aurinia Pharma Surges 9% On Priority Review For Lupus Kidney Treatment
Shares in Aurinia Pharma (AUPH) surged 9% in Tuesday’s extended trading after the U.S. Food and Drug Administration (FDA) accepted the filing of its New Drug Application (NDA) for voclosporin, a potential treatment for lupus nephritis (LN). This is a serious i
SmarterAnalyst · 07/22 08:03
Aurinia Pharma's voclosporin nabs accelerated review for kidney inflammation
Seeking Alpha - Article · 07/22 06:46
Aurinia Announces FDA Acceptance Of Filing Of New Drug Application And Priority Review For Voclosporin For Treatment Of Lupus Nephritis
Benzinga · 07/21 21:28